Mary O'Malley, PhD
Psychiatry · Sanford, MENPI 1649498742
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 16 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 30.0% of the total. Reporting peaked in 2024 at $245 and has fallen 84.3% since, to $38 in 2025.
Across 16 payments — averaging $24.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$116
- Indivior Inc.$81
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$59
- Eisai Inc.$45
- Biogen$28
- Otsuka America Pharmaceutical, Inc.$26
- plus $33 from 2 others
What the payments were for
- Food & beverage$387100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 3 | $116 |
| Indivior Inc. | 3 | $81 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $59 |
| Eisai Inc. | 3 | $45 |
| Biogen | 2 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $26 |
| AbbVie | 1 | $18 |
| Alkermes, Inc. | 1 | $14 |
How this compares
$387 in reported general payments places this provider in the 85th percentile of 167 psychiatry providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Olanzapine | 14 | $1,174 |
| Olanzapine OdtOlanzapine | 14 | $606 |
| Naltrexone Hcl | 16 | $466 |
| Divalproex Sodium ErDivalproex Sodium | 13 | $389 |
| Quetiapine Fumarate | 26 | $341 |
| Gabapentin | 30 | $334 |
| Hydroxyzine Hcl | 11 | $230 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 12 | $199 |
| Bupropion XlBupropion Hcl | 11 | $169 |
| Lamotrigine | 18 | $160 |
| Lithium Carbonate ErLithium Carbonate | 12 | $137 |
| Sertraline Hcl | 23 | $122 |
| Trazodone Hcl | 22 | $120 |
| Clonidine Hcl | 12 | $95 |
| Metformin Hcl | 18 | $52 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Sanford
- Lisa Sjodin-FeldmanSanford$356
- Ryan SmithEastport$92K
- Edward BilottiSouth Portland$88K
- Ira ScottBangor$27K
- Charmaine PatelBangor$17K
- Glenn CurrierPortland$8K
- Elliot GruenLewiston$7K
- David JonesArundel$5K
- Christine WhitePrinceton$2K
- Sally WeissBangor$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.